Literature DB >> 35380247

Computed tomographic enterography (CTE) in evaluating bowel involvement in patients with ovarian cancer.

Xiao-Mei Zhang1, Xin-Yu Zhang2, Yue-Xi Liu1, Ruo-Nan Li1, Yong-Mei Li3, Hua Linghu4.   

Abstract

PURPOSE: To explore the utility of CTE in the evaluation of bowel invasion in patients with primary ovarian, fallopian tube, and peritoneal cancer.
METHODS: This observational study included 73 patients who received CTE before operation between September 2019 and December 2021. Two radiologists reviewed CTE images, focusing on the sites and depth of bowel involvement. Based on the findings during surgical exploration, we evaluated the diagnostic power, like sensitivity, specificity, accuracy, positive predictive value (PPV), negative predictive value (NPV), positive likelihood ratio (+ LR), and negative likelihood ratio (- LR) of CTE. Additionally, the characteristic images of bowel involvement on CTE corresponding to surgical findings were shown in the study.
RESULTS: The rate of macroscopic bowel invasion in this cohort was 49.31% (36/73), of which eight patients had small bowel involvement, 17 patients had colon involvement and 27 patients had sigmoid-rectum involvement. CTE detected bowel invasion in the small intestine with a sensitivity, specificity, PPV, NPV, and accuracy of 87.50%, 92.31%, 58.33%, 98.36%, 91.78%; for colon, the statistics were 58.82%, 96.43%, 83.33%, 88.52%, 87.67% and for sigmoid-rectum 62.96%, 82.61%, 68.00%, 79.17%, 75.34%, respectively.
CONCLUSION: CTE appeared a preferable diagnostic power on the small bowel and colon invasion in patients with primary ovarian, fallopian tube, and peritoneal cancer.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Computed tomographic enterography; Debulking surgical procedures; Intestine; Ovarian carcinoma

Mesh:

Year:  2022        PMID: 35380247     DOI: 10.1007/s00261-022-03497-2

Source DB:  PubMed          Journal:  Abdom Radiol (NY)


  31 in total

1.  Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial.

Authors:  Sean Kehoe; Jane Hook; Matthew Nankivell; Gordon C Jayson; Henry Kitchener; Tito Lopes; David Luesley; Timothy Perren; Selina Bannoo; Monica Mascarenhas; Stephen Dobbs; Sharadah Essapen; Jeremy Twigg; Jonathan Herod; Glenn McCluggage; Mahesh Parmar; Ann-Marie Swart
Journal:  Lancet       Date:  2015-05-19       Impact factor: 79.321

2.  Neo-adjuvant chemotherapy does not increase the rate of complete resection and does not significantly reduce the morbidity of Visceral-Peritoneal Debulking (VPD) in patients with stage IIIC-IV ovarian cancer.

Authors:  Roberto Tozzi; Raffaella Giannice; Stefano Cianci; Sarah Tardino; Riccardo Garruto Campanile; Kumar Gubbala; Giorgio Fachechi; Federico Ferrari; Igor Martinek; Hooman Soleymani Majd
Journal:  Gynecol Oncol       Date:  2015-05-21       Impact factor: 5.482

3.  Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer.

Authors:  Ignace Vergote; Claes G Tropé; Frédéric Amant; Gunnar B Kristensen; Tom Ehlen; Nick Johnson; René H M Verheijen; Maria E L van der Burg; Angel J Lacave; Pierluigi Benedetti Panici; Gemma G Kenter; Antonio Casado; Cesar Mendiola; Corneel Coens; Leen Verleye; Gavin C E Stuart; Sergio Pecorelli; Nick S Reed
Journal:  N Engl J Med       Date:  2010-09-02       Impact factor: 91.245

4.  Role of rectosigmoidectomy and stripping of pelvic peritoneum in outcomes of patients with advanced ovarian cancer.

Authors:  Giovanni D Aletti; Karl C Podratz; Monica B Jones; William A Cliby
Journal:  J Am Coll Surg       Date:  2006-08-23       Impact factor: 6.113

5.  The effect of bowel resection on survival in advanced epithelial ovarian cancer.

Authors:  W Jaeger; S Ackermann; H Kessler; A Katalinic; N Lang
Journal:  Gynecol Oncol       Date:  2001-11       Impact factor: 5.482

6.  Rectosigmoidectomy and Douglas Peritonectomy in the Management of Serosal Implants in Advanced-Stage Ovarian Cancer Surgery: Survival and Surgical Outcomes.

Authors:  Selçuk Erkilinç; Volkan Karataşli; Batuhan Demir; İlker Çakir; Behzat Can; Tuğba Karadeniz; Mehmet Gökçü; Muzaffer Sanci
Journal:  Int J Gynecol Cancer       Date:  2018-11       Impact factor: 3.437

7.  Trends and age-period-cohort effects on mortality of the three major gynecologic cancers in China from 1990 to 2019: Cervical, ovarian and uterine cancer.

Authors:  Zhenkun Wang; Ensong Guo; Bin Yang; Rourou Xiao; Funian Lu; Lixin You; Gang Chen
Journal:  Gynecol Oncol       Date:  2021-09-08       Impact factor: 5.482

8.  Prognostic role of bowel involvement in optimally cytoreduced advanced ovarian cancer: a retrospective study.

Authors:  Giorgio Giorda; Angiolo Gadducci; Emilio Lucia; Roberto Sorio; Valentina E Bounous; Francesco Sopracordevole; Andrea Tinelli; Gustavo Baldassarre; Elio Campagnutta
Journal:  J Ovarian Res       Date:  2014-07-09       Impact factor: 4.234

9.  Depth of colorectal-wall invasion and lymph-node involvement as major outcome factors influencing surgical strategy in patients with advanced and recurrent ovarian cancer with diffuse peritoneal metastases.

Authors:  Angelo Di Giorgio; Maurizio Cardi; Daniele Biacchi; Simone Sibio; Fabio Accarpio; Antonio Ciardi; Tommaso Cornali; Marialuisa Framarino; Paolo Sammartino
Journal:  World J Surg Oncol       Date:  2013-03-09       Impact factor: 2.754

10.  Survival impact of low anterior resection in patients with epithelial ovarian cancer grossly confined to the pelvic cavity: a Korean multicenter study.

Authors:  Miseon Kim; Dong Hoon Suh; Jeong Yeol Park; E Sun Paik; Seungmee Lee; Kyung Jin Eoh; Joo Hyun Nam; Yoo Young Lee; Jae Weon Kim; Sunghoon Kim
Journal:  J Gynecol Oncol       Date:  2018-04-13       Impact factor: 4.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.